EdgarLookup

TuHURA Biosciences, Inc./NV — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that TuHURA Biosciences, Inc./NV filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Financials Insiders
-108.6%
Return on Assets
Net income ÷ assets
0.37x
Debt-to-Equity
Total liabilities ÷ equity

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $0 Mar 31, 2025
FY2024 Dec 31, 2023 $0 Mar 31, 2025
FY2012 Jun 30, 2012 $0 Dec 20, 2012
FY2012 Jun 30, 2011 $0 Dec 20, 2012

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($21.68M) Mar 31, 2025
FY2024 Jun 30, 2024 ($8.32M) Oct 7, 2024
FY2024 Dec 31, 2023 ($29.32M) Mar 31, 2025
FY2024 Jun 30, 2023 ($14.65M) Oct 7, 2024
FY2023 Jun 30, 2022 ($22.66M) Sep 18, 2023
FY2022 Jun 30, 2021 ($38.30M) Sep 27, 2022
FY2021 Jun 30, 2020 ($9.13M) Sep 28, 2021
FY2020 Jun 30, 2019 ($8.05M) Sep 18, 2020
FY2019 Jun 30, 2018 $11.14M Sep 9, 2019
FY2018 Jun 30, 2017 $8.08M Sep 24, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2012 Jun 30, 2012 ($982) Dec 20, 2012
FY2012 Jun 30, 2011 ($6.8K) Dec 20, 2012

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $19.97M Mar 31, 2025
FY2024 Jun 30, 2024 $6.20M Oct 7, 2024
FY2024 Dec 31, 2023 $4.36M Mar 31, 2025
FY2024 Jun 30, 2023 $3.98M Oct 7, 2024
FY2023 Jun 30, 2022 $15.95M Sep 18, 2023
FY2022 Jun 30, 2021 $13.54M Sep 27, 2022
FY2021 Jun 30, 2020 $2.94M Sep 28, 2021
FY2020 Jun 30, 2019 $4.04M Sep 18, 2020
FY2019 Jun 30, 2018 $7.07M Sep 9, 2019
FY2018 Jun 30, 2017 $7.91M Sep 24, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $5.37M Mar 31, 2025
FY2024 Jun 30, 2024 $2.45M Oct 7, 2024
FY2024 Dec 31, 2023 $5.92M Mar 31, 2025
FY2024 Jun 30, 2023 $3.25M Oct 7, 2024
FY2023 Jun 30, 2022 $4.15M Sep 18, 2023
FY2022 Jun 30, 2021 $2.96M Sep 27, 2022
FY2021 Jun 30, 2020 $2.68M Sep 28, 2021
FY2020 Jun 30, 2019 $2.07M Sep 18, 2020
FY2019 Jun 30, 2018 $1.64M Sep 9, 2019
FY2018 Jun 30, 2017 $1.33M Sep 24, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $14.59M Mar 31, 2025
FY2024 Jun 30, 2024 $3.76M Oct 7, 2024
FY2024 Dec 31, 2023 ($1.56M) Mar 31, 2025
FY2024 Jun 30, 2023 $731.0K Oct 7, 2024
FY2024 Dec 31, 2022 $12.30M Mar 31, 2025
FY2024 Jun 30, 2022 $11.80M Oct 7, 2024
FY2023 Jun 30, 2021 $10.58M Sep 18, 2023
FY2022 Jun 30, 2020 $263.0K Sep 27, 2022
FY2021 Jun 30, 2019 $1.97M Sep 28, 2021
FY2020 Jun 30, 2018 $5.44M Sep 18, 2020

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 (1) Mar 31, 2025
FY2024 Jun 30, 2024 0 Oct 7, 2024
FY2024 Dec 31, 2023 (2) Mar 31, 2025
FY2024 Jun 30, 2023 (9) Oct 7, 2024
FY2023 Jun 30, 2022 (25) Sep 18, 2023
FY2022 Jun 30, 2021 (1) Sep 27, 2022
FY2021 Jun 30, 2020 0 Sep 28, 2021
FY2020 Jun 30, 2019 3 Sep 18, 2020
FY2019 Jun 30, 2018 5 Sep 9, 2019
FY2018 Jun 30, 2017 0 Sep 24, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 (1) Mar 31, 2025
FY2024 Dec 31, 2023 (2) Mar 31, 2025
FY2015 Jun 30, 2015 0 Nov 16, 2015
FY2015 Jun 30, 2014 0 Nov 16, 2015

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $12.66M Mar 31, 2025
FY2024 Jun 30, 2024 $4.91M Oct 7, 2024
FY2024 Dec 31, 2023 $3.67M Mar 31, 2025
FY2024 Jun 30, 2023 $1.54M Oct 7, 2024
FY2023 Jun 30, 2022 $11.78M Sep 18, 2023
FY2022 Jun 30, 2021 $10.54M Sep 27, 2022
FY2021 Jun 30, 2020 $2.39M Sep 28, 2021
FY2020 Jun 30, 2019 $3.72M Sep 18, 2020
FY2019 Jun 30, 2018 $5.97M Sep 9, 2019
FY2019 Jun 30, 2017 $6.59M Sep 9, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2019 Jun 30, 2018 $1.1K Sep 9, 2019
FY2018 Jun 30, 2017 $28.1K Sep 24, 2018
FY2017 Jun 30, 2016 $693.7K Sep 27, 2017